Slide background

Slide background
Slide background
Slide background

Loading Events
Meet with…Canaan Partners

10:30 AM — 1:00 PM
Featured Presenter: Colleen Cuffaro, PhD | Principal, Canaan Partners   Canaan Partners is an early...
See New York Genome Center’s lecture series, events and archives VIEW FULL CALENDAR


Featured Presenter: Colleen Cuffaro, PhD | Principal, Canaan Partners


Canaan Partners is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With $4.2 billion under management, a diversified fund and 190 exits to date, Canaan has funded some of the world’s leading technology companies including LendingClub, Ebates, PrimeSense, and Skybox Imaging as well as healthcare stars like Chimerix, Durata, Labrys Biologics, Novira, CytomX and Civitas Therapeutics. Canaan is currently investing in a $675 million fund focused on early stage IT and healthcare startups. The fund’s healthcare focus includes early stage biopharma, medical devices and digital health.


10:30 AM | Registration Opens and Networking
11:00 AM | Presentation and Q&A
11:45 AM | Networking Lunch
1:00 PM -5:00 PM | One-on-one Meetings*


Presentation & Lunch
$ 25 | General Public
$ 35 | General Public Onsite


Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status.

Pre-registration to attend the presentation, Q&A, and lunch will remain open until noon on June 26th (or sold out).






One-on-One Meeting:
FREE | Application
FREE | Accepted Companies


Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period ends on June 1st. Your application will be reviewed and you will be notified of acceptance by email. Acceptance of one-on-one meetings is not guaranteed as all applications must be approved.


*Dr. Cuffaro will be on-hand to meet with a handful of applicants one-on-one after the presentation.







New York Genome Center
101 6th Ave
1st Floor
New York, NY 10013



Presenter’s Biography:

Colleen Cuffaro, PhD | Principal, Canaan Partners

Dr. Colleen Cuffaro is a Principal on Canaan’s Healthcare Team. She recently led Canaan’s investment in Arrakis Therapeutics and sits on their board. She holds an operational role at Antiva Biosciences and observes on the boards of Spyryx Biosciences, NextCure and Arvinas. Previously, she was a board observer at Novira Therapeutics which was acquired by Johnson & Johnson. Prior to joining Canaan in 2014, Dr. Cuffaro worked as a chemist at PMRS, Inc (Pharmaceutical Manufacturing and Research Services, Inc). Her responsibilities included analytical support of drug product development, ranging from preclinical feasibility studies to commercial supply.


She also interned as a bioscience analyst for the inaugural class of Entrepreneurship Lab NYC, an accelerator program for healthcare startups.Dr. Cuffaro holds a Ph.D. in Cellular and Molecular Physiology from Yale University, where her research was aimed at identifying a role for aberrant intracellular calcium signals in the development of metabolic syndrome. She served as co-president of the Yale Healthcare and Life Sciences Club and organized the annual Yale Business of Biotech seminar.Dr. Cuffaro also holds a B.A. in Chemistry from the University of Pennsylvania.


About the Meet with… Series:
The purpose of the Meet with series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started.


Past participants include the Wellcome Trust, Bill and Melinda Gates Foundation, MedImmune Ventures, Mercury Fund, DARPA’s Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCI, NCATS, NINDS, Allegory Venture Partners, Clarus Ventures, Johnson & Johnson Innovation, Poliwogg, California Institute for Regenerative Medicine, Astellas Venture Management, OrbiMed, Osage University Partners, Spectrum 28, Quark Venture and AbbVie Ventures.

  • +

    • Let us go on again, and plunge into the Five Points. — Charles Dickens, 1842

      Named for an early Manhattan crossroads – remembered as a rowdy but cosmopolitan gathering place, and as a nexus for progress in public health – the Five Points Lectures bring outstanding scientists from near and far, to discuss their work in technical detail* with researchers and clinicians from institutions served by NYGC, in order to strengthen our grasp of key biological questions and methods. Speakers present fresh and intriguing findings, along with thoughtful views on their respective fields, in full scientific depth. Talks last roughly 45 minutes — often framing five or so key points, in a nod to the series’ name — followed by 15 minutes of open Q&A, and 30 minutes of networking.

  • +
  • +